Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. - Wikidata - wikimedia - TriplyDB

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases.

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases.

http://www.wikidata.org/entity/Q35071710

about

T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.Neurotrophic Factors and Their Potential Applications in Tissue Regeneration.Developing Extracellular Matrix Technology to Treat Retinal or Optic Nerve Injury(1,2,3)Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background The role of neurotrophins in multiple sclerosis-pathological and clinical implications Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain.Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.Expression of Placental Neurotrophin-3 (NT-3) in Physiological Pregnancy, Preeclampsia and Chorioamnionitis A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.HBZ stimulates brain-derived neurotrophic factor/TrkB autocrine/paracrine signaling to promote survival of human T-cell leukemia virus type 1-Infected T cells Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis.Molecular pathogenesis of neuroinflammation.Ischaemic preconditioning: therapeutic implications for stroke?Remyelinating and neuroprotective treatments in multiple sclerosis.Immunologic factors in primary progressive multiple sclerosis.Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment Mitoxantrone (Novantrone) in multiple sclerosis: new insights.Neural stem cells in inflammatory CNS diseases: mechanisms and therapy.Glatiramer acetate in multiple sclerosis.Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis.Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.Role of immune cells in animal models for inherited peripheral neuropathies.A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia.Reciprocal regulation between natural killer cells and autoreactive T cells.An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles.Nucleus accumbens invulnerability to methamphetamine neurotoxicity.Glatiramer in the treatment of multiple sclerosis Human autoantibodies specific for neurotrophin receptors TrkA, TrkB, and TrkC protect against lethal Trypanosoma cruzi infection in mice.Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.Boosting controlled autoimmunity: a new therapeutic target for CNS disorders.The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review.The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis.Microglia and neuroprotection.

P2860

Q24562400-7840CA90-F725-4454-B001-A98901F771E2 Q26776474-7C92C5CF-9E0E-49EE-A623-6200168454A6 Q26781911-FE2FA87E-25DB-4331-AAF7-15F9BB5CC48B Q26801046-4B7E9F5B-E544-443D-A86B-E9AB0402F34D Q26849274-EFBCB179-9926-4E4E-8831-63C59F59C151 Q28308287-F04EBA2E-4BAE-45BE-8172-859BDE93955C Q30477260-627CE14B-F6D8-4A88-BB3D-49871EF7C6B6 Q30584811-D20176E5-2CC7-4FD1-A8B3-5EA69E040195 Q31101744-D681E675-C125-40E7-A7E3-521FD74295D4 Q33578739-DE8774C7-399A-4D83-8C04-A857F1C397EA Q34342657-C725813C-8638-495A-9309-F54875937737 Q34405264-AC2DF25D-D648-4724-9D19-0FBBF211DDC6 Q34594557-DC9FCC9C-320B-40AD-A191-03C9142D7DAD Q34784469-93554E1C-AA96-4B14-8542-E0C6ECFDF3B6 Q35094706-DDD90CF4-71CD-4C8D-A75F-C3EB706FEFAF Q35097450-35AFFFCF-E79B-4564-8833-F7452B4ADCF9 Q35564938-7264B05C-1411-4753-8C5E-8394569ADF4E Q35753366-802D4EFE-A8E1-48AB-9AAB-B0BF563388CD Q35753458-DB1520D1-F1D5-4FB5-BB65-0EC1969D9A6D Q35818135-EB594AEA-D3E6-437D-9E97-275F42FB3D5F Q35861182-3000614C-015B-4F99-9279-AA9E7621EBE1 Q35967384-B0E34135-4A95-42A8-A9C3-0822A239EC04 Q36099316-ED85C760-D65E-41D1-92CE-AE4627F30F5A Q36107235-6563D821-C428-4282-A759-1952EC8455B7 Q36166488-F1271D49-A495-482E-AE62-84A4D6C2D9E6 Q36198583-11E4008D-173C-4198-9E2B-9A4EDBA35E86 Q36299378-BFB58852-4A39-4D73-A5F7-09542DA961E1 Q36329275-6EC5311B-9D14-48B2-874A-C6120FAC42B8 Q36507170-B725E540-ACA8-4C5D-95CB-6CA24D99E456 Q36600804-9A68F624-6EC0-4D2F-8C9E-D4258A3E5D13 Q36602589-6D641598-2C95-4A35-8A8E-4C273C2D62C9 Q36651048-9D5967F0-0517-4520-84A3-726B53FFF0E0 Q36702400-1BF88284-9DB6-462B-9499-ACB1222B27B5 Q36918770-6998A6D8-A207-4156-98E3-648AB65F8E73 Q36943082-9C28C0B2-0B19-4336-B815-BF5AA8DF9454 Q36963184-22EE4E8C-7B7A-4728-AA83-86EEAADA00BB Q37154818-788FC9ED-EECF-4727-B8F1-942DE68A43C5 Q37820180-EAF87D01-0E45-4893-BD25-F91F99EC8648 Q37982954-BF0A7754-E8D5-4118-9256-49189D79B60D Q38360452-AB8E2B46-3BCF-4CEA-A42A-A37D354ED961

P2860

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases.

http://www.wikidata.org/entity/Q35071710

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@ast

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@en

type

label

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@ast

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@en

prefLabel

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@ast

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@en

P1433

Q35071710-1EDAE09E-B3BB-4476-B22E-D70875E08FD0

P1476

Q35071710-0A2FB7C1-C526-40D6-9E5A-F209DED8AA81

P2093

Q35071710-38670ECD-9C57-41B9-BF6E-C4E521384FB1

Q35071710-9292A95C-0BDE-4B05-AFFC-125791A15D8F

Q35071710-93CEAB4D-6301-41A5-9F63-0D4345F52C21

Q35071710-A0178EFD-E184-4E34-AE5B-6CE85F76E92E

Q35071710-C1D2E092-3CC3-45C3-9909-39CA33A6266D

P2860

Q35071710-0B6A9FE4-8022-461E-9451-876CE570F3FA

Q35071710-1470E748-CE85-47E8-8718-43F7522D87B4

Q35071710-1FF204CA-2B84-4E46-80B3-F100420FF535

Q35071710-4DAB7B4C-E218-45EB-86F7-2863BCC9A012

Q35071710-9746FA4D-226F-4E82-897D-777733A50CB8

Q35071710-9C3FDCA7-71D0-4494-8FFA-D22A31D922B9

Q35071710-A0056389-A0E0-482F-B1C7-7942721D9B2B

Q35071710-A4C06A4D-79B9-4221-A60F-1AA7C47D69D2

Q35071710-CFF97BF1-5E47-48C1-A585-C94041598D12

Q35071710-E51E5BC3-7553-4D05-AC4D-82DAB4BD3CC4

P304

Q35071710-5C33343A-6621-4FF8-AFDC-E49D09BDF1E2

P31

Q35071710-252E6165-5437-4D87-97FA-AFFC8349C7CF

P356

Q35071710-9C9B2849-0BD2-4738-9431-0C32AA488478

P433

Q35071710-68D24AD9-56CB-4E33-8F9E-FD7702407DC3

P478

Q35071710-A7B72EB3-D3FE-40E1-A442-80DEB8580A50

P577

Q35071710-2BEC3731-FEFB-4C57-A357-43A9B479CBC1

P698

Q35071710-4DA3F743-961D-4C85-8D2A-6DFFA412C7DC

P356

P1433

Annals of Neurology

P1476

Neurotrophic cross-talk betwee ...... ons for neurological diseases.

@en

P2093

Christine Stadelmann

http://www.w3.org/2001/XMLSchema#string

Georg Dechant

http://www.w3.org/2001/XMLSchema#string

Hartmut Wekerle

http://www.w3.org/2001/XMLSchema#string

Martin Kerschensteiner

http://www.w3.org/2001/XMLSchema#string

Reinhard Hohlfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination.

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies.

Intracellular signaling pathways activated by neurotrophic factors.

Evolving stroke and the ischemic penumbra.

Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity.

Enhanced expression of NGF receptors in multiple sclerosis lesions.

Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation.

The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy.

Effects of brain-derived neurotrophic factor (BDNF) on compression-induced spinal cord injury: BDNF attenuates down-regulation of superoxide dismutase expression and promotes up-regulation of myelin basic protein expression.

Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

P304

292-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.10446

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12601697

http://www.w3.org/2001/XMLSchema#string